GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival

The use of mutant strains of oncolytic herpes simplex virus (oHSV) in early-phase human clinical trials for the treatment of glioblastoma multiforme (GBM) has proven safe, but limited efficacy suggests that more potent vector designs are required for effective GBM therapy. Inadequate vector performa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sette, Paola, Amankulor, Nduka, Li, Aofei, Marzulli, Marco, Leronni, Daniela, Zhang, Mingdi, Goins, William F., Kaur, Balveen, Bolyard, Chelsea, Cripe, Timothy P., Yu, Jianhua, Chiocca, E. Antonio, Glorioso, Joseph C., Grandi, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926261/
https://www.ncbi.nlm.nih.gov/pubmed/31890868
http://dx.doi.org/10.1016/j.omto.2019.10.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926261/
https://www.ncbi.nlm.nih.gov/pubmed/31890868
http://dx.doi.org/10.1016/j.omto.2019.10.005

Ejemplares similares